Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors

Breast Cancer Research

Volumn 14, Issue 6, 2012, Pages

  Cañas, Amanda ^a   López Sánchez, Laura M ^b   Valverde Estepa, Araceli ^a   Hernández, Vanessa ^a   Fuentes, Elena ^a   Muñoz Castañeda, Juan R ^a   López Pedrera, Chary ^a   De La Haba Rodríguez, Juan R ^a   Aranda, Enrique ^a   Rodríguez Ariza, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HERMES ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PIFITHRIN ALPHA; PROTEIN KINASE B; PROTEIN P53; RNA; S NITROSOTHIOL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTIRHEUMATIC AGENT; BENZOTHIAZOLE DERIVATIVE; CCND1 PROTEIN, HUMAN; CD24 ANTIGEN; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; CYSTEINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PIFITHRIN; S-NITROSOCYSTEINE; SMALL INTERFERING RNA; THIOREDOXIN REDUCTASE; TOLUENE;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE SILENCING; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CHEMISTRY; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL CULTURE;

ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIRHEUMATIC AGENTS; AURANOFIN; BENZOTHIAZOLES; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYSTEINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HOMEOSTASIS; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; S-NITROSOTHIOLS; SPHEROIDS, CELLULAR; THIOREDOXIN-DISULFIDE REDUCTASE; TOLUENE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870342895     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3366     Document Type: Article

References (39)

1. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, Loscalzo J. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992, 89:444-448. 10.1073/pnas.89.1.444, 48254, 1346070.
2. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001, 3:193-197. 10.1038/35055104, 11175752.
3. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009, 15:391-404. 10.1016/j.molmed.2009.06.007, 3106339, 19726230.
4. Benhar M, Forrester MT, Stamler JS. Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol 2009, 10:721-732.
5. Stamler JS, Hess DT. Nascent nitrosylases. Nat Cell Biol 2010, 12:1024-1026. 10.1038/ncb1110-1024, 20972426.
6. Sengupta R, Ryter SW, Zuckerbraun BS, Tzeng E, Billiar TR, Stoyanovsky DA. Thioredoxin catalyzes the denitrosation of low-molecular mass and protein S-nitrosothiols. Biochemistry 2007, 46:8472-8483. 10.1021/bi700449x, 17580965.
7. Benhar M, Forrester MT, Hess DT, Stamler JS. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 2008, 320:1050-1054. 10.1126/science.1158265, 2754768, 18497292.
8. Tello D, Tarin C, Ahicart P, Breton-Romero R, Lamas S, Martinez-Ruiz A. A 'fluorescence switch' technique increases the sensitivity of proteomic detection and identification of S-nitrosylated proteins. Proteomics 2009, 9:5359-5370. 10.1002/pmic.200900070, 19798666.
9. Lopez-Sanchez LM, Corrales FJ, Lopez-Pedrera C, Aranda E, Rodriguez-Ariza A. Pharmacological impairment of S-nitrosoglutathione or thioredoxin reductases augments protein S-nitrosation in human hepatocarcinoma cells. Anticancer Res 2010, 30:415-421.
10. Lima B, Forrester MT, Hess DT, Stamler JS. S-nitrosylation in cardiovascular signaling. Circ Res 2010, 106:633-646. 10.1161/CIRCRESAHA.109.207381, 2891248, 20203313.
11. Ckless K, Lampert A, Reiss J, Kasahara D, Poynter ME, Irvin CG, Lundblad LK, Norton R, van der Vliet A, Janssen-Heininger YM. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol 2008, 181:4255-4264. 2892856, 18768883.
12. Wu H, Romieu I, Sienra-Monge JJ, Estela Del Rio-Navarro B, Anderson DM, Jenchura CA, Li H, Ramirez-Aguilar M, Del Carmen Lara-Sanchez I, London SJ. Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. J Allergy Clin Immunol 2007, 120:322-328. 10.1016/j.jaci.2007.04.022, 2094003, 17543375.
13. Lopez-Sanchez LM, Corrales FJ, Barcos M, Espejo I, Munoz-Castaneda JR, Rodriguez-Ariza A. Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis. Lab Invest 2010, 90:116-127. 10.1038/labinvest.2009.104, 19806079.
14. Nakamura T, Lipton SA. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ 2011, 18:1478-1486. 10.1038/cdd.2011.65, 3178424, 21597461.
15. Sarkar S, Korolchuk VI, Renna M, Imarisio S, Fleming A, Williams A, Garcia-Arencibia M, Rose C, Luo S, Underwood BR, Kroemer G, O'Kane CJ, Rubinsztein DC. Complex inhibitory effects of nitric oxide on autophagy. Mol Cell 2011, 43:19-32. 10.1016/j.molcel.2011.04.029, 3149661, 21726807.
16. Wei W, Li B, Hanes MA, Kakar S, Chen X, Liu L. S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med 2010, 2:19ra13. 10.1126/scitranslmed.3000328, 3085984, 20371487.
17. Aranda E, Lopez-Pedrera C, De La Haba-Rodriguez JR, Rodriguez-Ariza A. Nitric oxide and cancer: the emerging role of S-nitrosylation. Curr Mol Med 2012, 12:50-67. 10.2174/156652412798376099, 22082481.
18. Shah CM, Locke IC, Chowdrey HS, Gordge MP. Rapid S-nitrosothiol metabolism by platelets and megakaryocytes. Biochem Soc Trans 2003, 31:1450-1452. 10.1042/BST0311450, 14641087.
19. Mcgill R, Tukey JW, Larsen WA. Variations of box plots. Am Stat 1978, 32:12-16.
20. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 2002, 22:5835-5845. 10.1128/MCB.22.16.5835-5845.2002, 133965, 12138194.
21. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
22. Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, Kuperwasser C. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 2010, 107:21737-21742. 10.1073/pnas.1007863107, 3003123, 21098263.
23. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
24. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011, 10:3871-3885. 10.4161/cc.10.22.17976, 22127234.
25. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R, Badve S, Srour EF, Nakshatri H. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 2010, 10:411. 10.1186/1471-2407-10-411, 3087321, 20691079.
26. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008, 47:600-607. 10.1080/02841860802047411, 18465328.
27. Bremer TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP. Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients. Int J Cancer 2009, 124:896-904. 10.1002/ijc.24001, 19035452.
28. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
29. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003, 10:179-186. 10.1677/erc.0.0100179, 12790780.
30. Rao AK, Ziegler YS, McLeod IX, Yates JR, Nardulli AM. Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells. J Mol Endocrinol 2009, 43:251-261. 10.1677/JME-09-0053, 2994277, 19620238.
31. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993, 106(Pt 4):1377-1388.
32. Nonclercq D, Journe F, Body JJ, Leclercq G, Laurent G. Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways. Mol Cell Endocrinol 2004, 227:53-65. 10.1016/j.mce.2004.07.003, 15501584.
33. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011, 11:597-608. 10.1038/nrc3093, 21779010.
34. Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA, Napolitano M, Nola E, Moncharmont B, Medici N, Nigro V, Armetta I, Abbondanza C, Puca GA. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 2000, 60:2594-2597.
35. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006, 281:9837-9840. 10.1074/jbc.C600001200, 16469747.
36. Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA, Das GM. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA 2010, 107:15081-15086. 10.1073/pnas.1009575107, 2930589, 20696891.
37. Matsutani Y, Yamauchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K, Nakamura H, Kato H, Kodama H, Inamoto T, Yodoi J, Yamaoka Y. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 2001, 7:3430-3436.
38. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahnenfuhrer J, Baumbach JI, Sickmann A, Hengstler JG. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 2010, 12:R44. 10.1186/bcr2599, 2917039, 20584310.
39. Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 2003, 10:112-119. 10.1007/BF02967635, 12736563.